ⓘ Denintuzumab mafodotin

                                     

ⓘ Denintuzumab mafodotin

Denintuzumab mafodotin is a humanized monoclonal antibody-drug conjugate designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl auristatin F, a cytotoxic agent. This drug was developed by Seattle Genetics.

Denintuzumab refers to the anti-content of lymphocytes CD19 antibodies, and mafodotin refers to MMAF and chemical bonding.